… efficacy in successful anticoagulation reversal than the 4F-… reversing anticoagulation in
patients with ICH. Our findings showed a higher success rate of AA in reversing anticoagulation (…

… FXi anticoagulation, expert opinion recommends using either 4F-PCC or AA to reverse the
anticoagulation … or experimental studies to select the best reversal approach to pursue in this …

… Dosing algorithm for use of andexanet alfa is shown in Fig. 1. At DUH, an anticoagulant
screen includes an anti-factor Xa level calibrated with unfractionated heparin/low molecular …

… or 4F-PCC to reverse factor Xa inhibitor-associated acute major … potential superiority
between the two reversal agents. [12] … with a reversal agent to resumption of anticoagulation. …

… specific FXa inhibitor reversal agent, recombinant FXa (Andexanet alfa), … anticoagulation
reversal is required for patients with uncontrolled or life-threatening bleeding [8]. Andexanet alfa …

… Even ANNEXA-4, 10 , 23 a prospective study that served to support the FDA approval of
andexanet alfa for reversal of anticoagulation with FXa-I in patients with life-threatening bleeding…

… factor Xa inhibitor‐associated intracranial hemorrhages (ICH) treated with andexanet alfa
or … The most common baseline anticoagulant was apixaban in the andexanet alfa cohort (83.3…

… factor Xa inhibitor-associated hemorrhages. In 2018, the FDA approved andexanet alfa as
the first reversal … medications than innate factor Xa, which negates their anticoagulant effect [7]…

… Although andexanet was designed as an antidote for apixaban and … , andexanet had near
full reversal of heparin, reversed anti–factor Xa activity, and neutralized anticoagulant effects …

… Andexanet alfa is approved (FDA “accelerated approval”; … specific reversal agent for factor
Xa (FXa) inhibitor-associated … oral anticoagulants (DOACs) and in particular the factor Xa (FXa…